维普中文期刊产品整合服务
494篇 您的检索式:作者名="Chakrabarty R"
    题名 作者 年代 出处 被引量
1Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial显示文摘AIM To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic parameters of nonalcoholic steatohepatitis(NASH).METHODS Twelve patients with biopsy-proven NASH were randomized to sitagliptin(100 mg daily)(n=6)or placebo(n=6)for 24 wk.The primary outcome was improvement in liver fibrosis after 24 wk.Secondary outcomes included evaluation of changes in NAFLD activity score(NAS),individual components of NAS(hepatocyte ballooning,lobular inflammation,and steatosis),glycemic control and insulin resistance[including measurements of glycated hemoglobin(Hb A1C)and adipocytokines],lipid profile including free fatty acids,adipose distribution measured using magnetic resonance imaging(MRI),and thrombosis markers(platelet aggregation and plasminogen activator inhibitor 1 levels).We also sought to determine the correlation between changes in hepatic fat fraction(%)[as measured using the Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation(IDEAL)MRI technique]and changes in hepatic steatosis on liver biopsy.RESULTS Sitagliptin was not significantly better than placebo at reducing liver fibrosis score as measured on liver biopsy(mean difference between sitagliptin and placebo arms,0.40,P=0.82).There were no significant improvements evident with the use of sitagliptin vs placebo for the secondary histologic outcomes of NAS total score as well as for the individual components of NAS.Compared to baseline,those patients who received sitagliptin demonstrated improved Hb A1C(6.7%±0.4%vs 7.9%±1.0%,P=0.02),and trended towards improved adiponectin levels(4.7±3.5μg/m L vs 3.9±2.7μg/m L,P=0.06)and triglyceride levels(1.26±0.43 mmol/L vs 2.80±1.64 mmol/L,P=0.08).However,when compared with placebo,sitagliptin did not cause a statistically significant improvement in Hb A1C(mean difference,-0.7%,P=0.19)nor triglyceride levels(mean difference-1.10mmol/L,P=0.19)but did trend towards improved adiponectin levels only(mean difference,0.60μg/m L,P=0.095).No significant changes in anthropometrics,liver enzymes,other adipocytokines,lipid profile,thrombosis parameters,or adipose distribution were demonstrated.The MRI IDEAL procedure correlated well with steatosis scores obtained on liver biopsy in both groups at baseline and post-treatment,and the Spearman correlation coefficients ranged from r=0.819(baseline)to r=0.878(post-treatment),P=0.002.CONCLUSION Sitagliptin does not improve fibrosis score or NAS after 24 wk of therapy.The MRI IDEAL technique may be useful for non-invasive measurement of hepatic steatosis.Tisha R Joy Charles A McKenzie Rommel G Tirona Kelly Summers Shannon Seney Subrata Chakrabarti Neel Malhotra Melanie D Beaton 2017World Journal of Gastroenterology2017,23,1:18
2Water wave scattering by an ice-strip 显示文摘Gayen R Mandal B N Chakrabarti A 2005J Engg Maths2005,53,1:1
3Relationship of air tempernature to various chemical,haematological and haemostatic variables显示文摘Bull G M Brozovic M Chakrabarti R 1979J Clin pathol1979,32,12:1
4Compact, synthetic, vaccinia virus early/late promoter for protein expression显示文摘Chakrabarti S Sisler J R Moss B 1997Biotechniques1997,23,6:1
5Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals显示文摘Scheid J F Mouquet H Feldhahn N Seaman M S Velinzon K Pietzsch J Ott R G Anthony R M Zebroski H Hurley A Phogat A Chakrabarti B Li Y Connors M Pereyra F Walker B D Wardemann H Ho D Wyatt R T Mascola J R Ravetch J V Nussenzweig M C 2009Nature2009,458,7238:1
6miR-195 regulates SIRTl-mediated changes in diabetic retinopathy 显示文摘Mortuza R Feng B Chakrabarti S et at 2014Diabetologia2014,57,5:1
7Evolutionary programming techniques for economic load dispatch显示文摘Sinha N Chakrabarti R Chattopadhyay P K 2003IEEE Trans on Evolutionary Computation2003,7,1:1
8Adjusted scaling of FDG positron emission tomography images for statistical evaluation in patients with suspected Alzheimer's disease 显示文摘Buchert R Wilke F Chakrabarti B 2005J Neuroimaging2005,15,:1
9Purification and charac-terization of phosphomannomutase/phosphoglucomutase from Pseudomonasaeruginosa involved in biosynthesis of both alginate and lipopolysaccharide显示文摘YE R W ZIELINSKI N A CHAKRABARTY A M 1994J Bacteriol1994,176,:1
10Aerosol light absorption and its measurement : a review 显示文摘MOOSMULLER H CHAKRABARTY R K ARNOTT W P 2009Journal of Quantitative Spectroscopy & Radiative Transfer2009,110,11:1
11Exchange rate expectations and foreign direct investment flows显示文摘Chakrabarti R Scholnick B 2002Review of World Economics2002,138,1:1
12PAT5A:a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic显示文摘Misra P Chakrabarti R Vikramadithyan R K 2003J Pharmacol Exp Ther2003,306,2:1
13显示文摘Chakrabarti R Das M Chakraborty D 2004J Appl Polym Sci2004,93,6:1
14A flavone glycoside, robinitin-7-O-β-D-glucopyranoside from Alternanthera sessilis显示文摘Sahu B R Chakrabarty Ajita 1993Asian Journal of Chemistry1993,5,4:1
15Super-resolution of face images using kernel PCA-based prior 显示文摘CHAKRABARTI A RAJAGOPALAN A N CHELLAPPA R 2007IEEE Transactions on Multimedia2007,9,4:1
16Mechanical and thermomechanical characterization of PVC/polyalkylacrylate blends显示文摘CHAKRABARTI R CHAKRABORTY D 2006J Appl Polym Sei2006,102,4:1
17Evolutionary programming techniques for economic load dispatch显示文摘Sinha N Chakrabarti R Chattopadhyay P K 2003IEEE Trans on Evolutionary Computation2003,7,1:1
18Fast evolutionary programming techniques for short-term hydrothermal scheduling 显示文摘Sinha N Chakrabarti R Chattopadhyay PK 2003IEEE Trans Power Systems2003,18,1:1
19Fuzziness in Rough Sets显示文摘Chakrabarty K Biswas R Nanda S 2000Fuzzy Sets and Systems2000,110,:1
20Pressure drop in liquid-liquid two phase horizontal flow:experiment and prediction显示文摘Chakrabarti D R Das G Ray S 2005ChemicalEngineering&Technology2005,28,9:1
返回顶部 每页显示:
共25页 首页 上一页 第1页 下一页 末页 /25 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费